Hertraz 440mg Injection

Hertraz 440mg Injection is a monoclonal antibody (Trastuzumab) used for treatment of HER2-positive cancers, mainly breast and gastric cancers.

Uses of Hertraz 440mg Injection:

• Gastric Cancer
• Breast Cancer

How does a Hertraz 440mg Injection work?

HER2 is a protein which is over-expressed on the surface of some cancer cells. Trastuzumab binds to HER2 to block tumour growth and inhibits signalling pathways that cause cells to grow and survive. It also causes the immune system to target the cells for destruction.

How to Use & Dosage

The usual dose is 8 mg/kg depending on the protocol followed by a maintenance dose of 6 mg/kg every three weeks. Given as an intravenous infusion; initial infusions should be administered slowly, in order to observe for adverse reactions.

It is administered by injection into a vein. It is given by a medical specialist in a hospital or clinic who has had special training.

This medicine may be given to children. Talk to the doctor before giving this medicine to your child. This medicine is not to be used in children.

Possible Side Effects:

• Nausea
• Vomiting
• Loss of appetite
• Diarrhea
• Fatigue
• Dizziness
• Sweating
• Stomatitis (mouth sores)
• Hand-foot syndrome
• Cardiotoxicity
• Liver enzyme elevation

Safety Advise:

🟤 Liver

Regular liver function tests are recommended as this drug can be toxic particularly in people who already have disease. Please consult with your healthcare provider.

🫘 Kidney

Periodic tests for kidney function are recommended as the drug can cause toxicity especially in patients with pre-existing conditions. Please talk to your healthcare provider.

🤰 Pregnancy

Hertraz is contraindicated in pregnancy because of the risk of fetal harm. Please speak with your healthcare provider.

🤱 Breastfeeding

Breastfeeding should be avoided. The drug may be excreted in breast milk. Please talk to your healthcare provider.

Storage Instructions:

Store Hertraz Injection in a refrigerator (2-8°C) and protect from light. Do not freeze.

References

Genentech, Inc. HERCEPTIN (Trastuzumab) for Injection: Highlights of Prescribing Information, Including Boxed Warning. U.S. Food and Drug Administration.

Slamon DJ, Leyland-Jones B, Shak S, et al. Use of Chemotherapy Plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. New England Journal of Medicine. 2001;344(11):783-792.

Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in Combination with Chemotherapy versus Chemotherapy Alone for Treatment of HER2-Positive Advanced Gastric or Gastro-Oesophageal Junction Cancer (ToGA). The Lancet. 2010;376(9742):687-697.

Brunton LL, Knollmann BC, eds. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education.

Tripathi KD. Essentials of Medical Pharmacology. 8th ed. New Delhi: Jaypee Brothers Medical Publishers.

Disclaimer:

IHS Enterprises’s primary objective is to guarantee the accuracy, reliability, and specialist review of the information it provides to customers. The contents and information provided on this website are for informational purposes only. They should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician for guidance and any questions you may have about any condition or medication. If you do read anything from IHS Enterprises, please do not discount or delay in seeking competent medical advice. We want to enhance the doctor-patient relationship, not substitute it.

Manufacturer details

Name: Mylan Pharmaceuticals Pvt Ltd – A Viatris Company

Address: Mylan Pharmaceuticals Private Limited, Commercial Operations, Prestige Tech Park, Platina-3, 7th to 12th floor, Prestige Tech Park, Kadubesanahalli, Bangalore -560103